Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled trial of KBP-5074 for uncontrolled hypertension in chronic kidney disease
MOH_2018-07-16_002524Phase 2Not yet recruiting
- Sponsor
- KBP Biosciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocederenone in hypertension (HTN) (3 arms), sponsored by KBP Biosciences. Primary endpoint: Change in seated cuff systolic blood pressure. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on MOH_2018-07-16_002524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-16_002524.